USSTOCK.TODAY
Pre-Market Log in Sign up

Biohaven resubmits Vyglxia approval application; FDA begins re-evaluation

BioPharma Dive · ·by G4L

BHVN
BHVN Biohaven Ltd
$13.65 +5.81%
View chart & analysis →
  1. 1Biohaven has resubmitted its Vyglxia approval application along with new positive supporting analyses.
  2. 2The FDA has convened an expert panel, with a new decision expected in the first quarter of next year.
  3. 3Despite a 70% figure regarding Vyglxia's ability to slow disease progression, the FDA officially rejected the treatment last November.

So what's the key point?

Biohaven has submitted paperwork to try to get approval for its drug again. Experts have gathered to start the review, and a result is expected early next year.

Source BioPharma Dive · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →